Al-Rubaie, M, Salek S, Walker S. Evaluation of the GCC centralised regulatory review process. Poster presentation; Philadelphia, PA, USA: Annual Meeting of the Drug Information Association, June 2012.
Leong J, McAuslane N, Walker S, Salek S. Development and application of a universal benefit-risk assessment framework for medicines. Poster presentation; Philadelphia, PA, USA: Annual Meeting of the Drug Information Association, June 2012.
Al-Rubaie M, Salek S, Walker S. Comparisons of the Gulf States’ and pharmaceutical companies’ perspectives on the effectiveness of the GCC centralised procedure. Poster presentation; Chicago, Illinois: Annual Drug Information Association Meeting, June, 2011.
Pichler F, Wang T. Benchmarking time and process in HTA and decision making. Poster presentation, Rio de Janeiro, Brazil: Health Technology Assessment International Annual Conference, June 2011.
Meister G, Yuvasheva E. The impact of FDA priority, accelerated, and fast-track reviews on approval times and postapproval regulatory activity. Poster presentation; Chicago, Illinois: Annual Drug Information Association Meeting, June 2011.
Patel P,McAuslane JAN, Liberti L. Agency activity and company strategy –How are these influencing time to market for new medicines in the emerging markets? Washington,DC: Annual Meeting of the Drug Information Association, June 2010.